A multicentre, prespective, randomized controlled study of efficacy and safety of decitabine combination with low dose CAG in patients with myelodysplastic syndrome

INTERVENTION: PR or CR:IAG, MA, DA, AA, CAG alteranated consolidation; CONDITION: myelodysplastic syndrome SECONDARY OUTCOME: Hematological improvement,cytogenetic response, overall survival and blood transfusion; INCLUSION CRITERIA: 1. Men and women, aged between 18 to 70 years; 2. Subjects have diagnosed the MDS, and IPSS >/= 0.5; 3. ECOG performance status (PS) score 0‐2; 4. AST and ALT <=2.5 times the institutional ULN; Total bilirubin <=2.0 times the institutional ULN Serum creatinine<2.0 times the institutional ULN; 5. Women or men must take effective contraceptive measures, in women Serum or urine pregnancy tests must be negative in the screening and study periods; 6. Men must take effective contraceptive measures during or after treatment within 6 months; 7. Patients understand the disease and voluntarily received the study regimen and follow‐up.